NCT01872923View on ClinicalTrials.gov

Dose Escalating Study for Amphinex-based PCI of Bleomycin.

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

February 28, 2013

Conditions
Cutaneous or Sub-cutaneous Malignancies
Interventions
DRUG

Amphinex

Photosensitiser

DRUG

Bleomycin

Anticancer agent

DEVICE

Laser

Laser that emits red light at 652 nm.

Trial Locations (1)

Unknown

University College London Hospital, London

Sponsors

Lead Sponsor

PCI Biotech AS
All Listed Sponsors
lead

PCI Biotech AS

INDUSTRY